Literature DB >> 3620925

Ganglioside-induced enhancement of behavioral recovery after bilateral lesions of the entorhinal cortex.

J J Ramirez, B Fass, T Kilfoil, B Henschel, W Grones, S E Karpiak.   

Abstract

Previous research has shown that exogenous gangliosides improve recovery of learned alternation after unilateral lesions of the entorhinal cortex. Since this recovery is thought to depend upon axonal sprouting, it has been hypothesized that ganglioside-induced improvement may be due to enhanced sprouting. The present study examined the effects of ganglioside treatments on learned alternation after bilateral entorhinal lesions. Whereas control rats exhibited a severe impairment postoperatively, ganglioside-treated (50 mg/kg total brain gangliosides; i.m.) rats committed significantly fewer errors and perseverative errors, and reached criterion sooner. The two groups exhibited comparable rates of daily improvement in performance. Since bilateral entorhinal lesions preclude the sprouting which is important for recovery of alternation, the ganglioside-induced improvement observed in the present study appears to be independent of sprouting.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620925     DOI: 10.1016/0006-8993(87)91328-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Effects of basic fibroblast growth factor and ganglioside GM1 on neuronal survival in primary cultures and on eight-arm radial maze task in adult rats following partial fimbria transections.

Authors:  A Iwashita; H Hisajima; Y Notsu; M Okuhara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

2.  Open field behaviours and spatial learning performance in C57BL/6 mice: early stage effects of chronic GM1 ganglioside administration.

Authors:  S Fagioli; C Rossi-Arnaud; M Ammassari-Teule
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.